Pharmaceutical raw material CAS No.654671-77-9 Sitagliptin phosphate monohydrate
What is Sitagliptin ?
Sitagliptin is one of the first won the U.S. food and drug administration approved for the treatment of type 2 diabetes dipeptide base peptidase (DDP - 4) inhibitor drugs, is a new type of diabetes, can increase the body's own ability to reduce high blood sugar levels, inhibit the enzyme activity and relatively improve shortness of naturally occurring intestinal insulin, including sample glucagon peptide 1 promote insulin and glucose dependence peptide levels, increased insulin production is triggering the pancreas and the liver to stop glucose production, and finally the clinical effect of lowering blood sugar concentration.This product is characterized by stimulating insulin secretion and reducing hunger, without weight gain, hypoglycemia and edema. It is suitable for diabetics with poor blood glucose control and frequent hypoglycemia.
| Name | Sitagliptin phosphate monohydrate,CAS 654671-77-9 |
| Structure |  |
| Other name | 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine Monohydrate, Sitagliptin Monophosphate Monohydrate, Sitagliptin Phosphate Monophosphate Monohydrate, Sitagliptin 654671-77-9 |
| Key words | Pharmaceutical ingredients, API; a pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR; HYPOGLYCEMIC AGENT; used in the treatment of TYPE 2 DIABETES |
| CAS NO. | 654671-77-9 |
| Molecular Formula | C16H20F6N5O6P |
| Molecular Weight | 523.329 g/mol |
| Application | |
| Drug Indication | For adult patients with type 2 diabetes mellitus, TESAVEL is indicated to improve glycaemic control |